MATRIX Discovery is Electrome's operating internal AI-native R&D software.
Specialized tools help scientists ground questions in evidence, compare hypotheses, rank candidate waveforms, model signals, design controlled experiments, and validate results. AI supports the work; people own the scientific decisions and every release gate.
Every cell in the human body communicates through electrical signals. From pain perception and inflammation to tissue repair and neurological activity, bioelectric signaling helps coordinate many of the body's most fundamental biological processes.
Electrome's platform is designed to study, model, and therapeutically influence these signaling systems using precisely engineered electromagnetic therapies and AI guided signal discovery.
Bioelectric medicine represents one of the most underexplored frontiers in modern therapeutics.
Advances in electrophysiology, computational biology, AI modeling, miniaturized electronics, and real world clinical data are enabling a new generation of programmable bioelectric therapeutics.
What was once difficult to observe is becoming measurable. What was once theoretical is becoming programmable.
Programmable medicine for the electrical era of biology, built layer by layer.
Pain and recovery anchor commercial entry. AI signal discovery extends the platform across biological systems.
Electrome's first commercial therapies focus on chronic pain, musculoskeletal recovery, and post surgical healing using non invasive pulsed electromagnetic field therapy designed to modulate inflammatory signaling and neural pain pathways.
Bioelectric signaling plays a critical role in tissue regeneration, circulation, inflammation control, and cellular recovery. Electrome is advancing therapies designed to support post surgical recovery, rehabilitation, and healing optimization.
Emerging research suggests bioelectric signaling may influence immune behavior, inflammation, cellular defense mechanisms, and microbial environments. Electrome is exploring how programmable electromagnetic therapies could contribute to future anti infective and immunomodulatory applications.
Cancer biology is deeply connected to cellular signaling behavior, membrane potential dynamics, and tissue communication networks. Electrome is researching how bioelectric modulation may contribute to future oncology supportive therapeutic strategies.
The brain operates through highly coordinated electrical activity. Electrome is exploring non invasive bioelectric approaches designed to support neurological performance, cognitive wellness, neural recovery, and future neurotherapeutic applications.
Electrome is building programmable bioelectric therapeutics designed to optimize retinal signaling, neuroinflammation, and visual system function through precision electromagnetic modulation.
ActiPatch is Electrome's first commercial therapy. A non invasive, drug-free, wearable bioelectric loop designed to modulate inflammatory signaling and neural pain pathways. FDA cleared. Clinically studied. Built for everyday use.
Electrome is helping advance a complementary therapeutic paradigm centered around the electrical behavior of biological systems. Programmable, data driven, non invasive therapies designed for the future of medicine.
Real world therapy generates clinical data. Clinical data sharpens signal intelligence. Signal intelligence unlocks new therapeutic discovery.
The next era of medicine will be programmable.
Research Pulse
Deeper background on bioelectric medicine, pulsed shortwave therapy, and the electrical language of biology lives in the Newsroom.
How membrane potentials, ion channels, and endogenous fields coordinate cellular communication.
Advances in electrophysiology, AI, and wearable electronics are making bioelectric signaling programmable.
Inflammation, neural communication, and tissue recovery, viewed through the lens of cellular signaling.
A primer on the field, the technologies, and the therapeutic categories it spans.
Why electrical signaling matters for tissue repair, inflammation modulation, and recovery.
Where wearable therapeutics, AI signal discovery, and clinical data are taking the platform.
Electrome's broader ecosystem includes commercial programs, pipeline initiatives, and exploratory research. These initiatives sit at varying stages of commercialization, pipeline development, and computational modeling. No efficacy claims are made regarding exploratory research programs.
This page is provided for scientific and informational purposes only. References to published studies, exploratory research, or FDA cleared technologies should not be interpreted as generalized efficacy claims. Statements regarding future applications, computational systems, and exploratory research initiatives are forward-looking and subject to scientific, clinical, and regulatory uncertainty.
A platform-selected candidate produced a measurable, replicated in-vitro result on the first day of experiments; peer-reviewed publication followed approximately six months after the initial laboratory work.
Erik A. Nilsen, Heather Adkison, John R. Martinez, Nevena Zubcevik, and Monica E. Embers
This preclinical in-vitro result does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people. No Electrome product is cleared or marketed for Lyme disease or any infectious condition.
Read the canonical research recordElectrome is building the infrastructure, therapies, and intelligence systems designed to help unlock the next frontier of programmable biology.
